I'm not sure what is meant by the phrase "used in later line therapies" since anacetrapib, RVX-208 and ETC-1002 are still awaiting Phase 3 Clinical Trial results and are not approved for use yet. Only ETC-1002 would directly compete with the anti-PCSK9 therapies, since both of those go after LDL lowering. Anacetrapib (CETP inhibitor) raises HDL but, like all other CETP inhibitor candidates, might be dead in the water and fail to show reduced cardiovasuclar events once its outcomes trial reads out later this year. 

We did discuss the Amgen PCSK9 Outcomes trial, as well as Esperion's ETC-1002 last month. Here are some links to the threads:

Amgen's Acclaimed 20% MACE reduction referred to as "slashing heart attack rates"

Esperion

RVX & Esperion